| Glaucoma Incidence Rates |
|
Females |
Males |
| Age 40–49 |
5 |
0.0028 |
0.0035 |
| Age 50–59 |
5 |
0.0030 |
0.0048 |
| Age 60–69 |
5 |
0.0066 |
0.0112 |
| Age 70+ |
5 |
0.0099 |
0.0114 |
|
| Glaucoma Progression |
|
|
| Annual probability of any field losses among people with glaucoma |
11 |
0.149 |
| Hazard ratio for progression if intra ocular pressure greater than 21 |
11 |
1.67 |
| Hazard ratio for progression if field loss in both eyes |
11 |
1.92 |
| Hazard ratio for progression if field loss the same eye |
11 |
1.46 |
| Hazard ratio for progression if age over 68 |
11 |
1.42 |
| dBs lost given any field loss occurs; min, mode, max |
11, Assumption |
0.2, 0.8, 3.0 |
|
| Treatment Contraindications |
|
|
| Asthma prevalence, males |
13 |
0.077 |
| Asthma prevalence, females |
13 |
0.101 |
| Reaction to Prostaglandin analogues |
14 |
0.1 |
| Reaction to Alpha-2 agonists |
15 |
0.3 |
|
| Treatment efficacy and duration of efficacy |
|
|
| Treatment effect: relative risk of progression |
11 |
0.60 |
| Treatment effect: relative risk for distribution of field loss |
11 |
0.826 |
| Annual failure rate of betablockers |
16 |
0.15 |
| Annual failure rate of prostaglandin |
16 |
0.17 |
| Annual failure rate of alpha-2 agonists |
17, Assumption |
0.4 |
| Annual failure rate of carbonic anhydrase inhibitors |
16 |
0.2 |
| Annual failure rate of laser trabeculoplasty |
18 |
0.066 |
| Annual failure rate of trabeculotomy |
18 |
0.052 |
|
| Sensitivity and specificity of examinations |
|
|
| Sensitivity of opthalmoscopy, <8 dBs lost |
19 |
0.81 |
| Specificity of opthalmoscopy, <8 dBs lost |
19 |
0.90 |
| Sensitivity of Automated Threshold Perimetry, <8 dBs lost |
20 |
0.93 |
| Specificity of ATP, <8 dBs lost |
20 |
0.88 |
| Sensitivity of opthalmoscopy, >8 dBs lost |
Assumption |
1.00 |
| Sensitivity of ATP, >8 dBs lost |
21 |
0.97 |
